AbbVie, Inc. (ABBV)
227.19
-1.52
(-0.66%)
USD |
NYSE |
Dec 05, 14:11
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 401.53B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 34.19% |
| Valuation | |
| PE Ratio | 171.43 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.746 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.73 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -26.02 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 21.89% |
Profile
| AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |
| URL | http://www.abbvie.com |
| Investor Relations URL | https://investors.abbvie.com |
| HQ State/Province | Illinois |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 06, 2026 (est.) |
| Last Earnings Release | Oct. 31, 2025 |
| Next Ex-Dividend Date | Jan. 16, 2026 |
| Last Ex-Dividend Date | Oct. 15, 2025 |
Ratings
Profile
| AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |
| URL | http://www.abbvie.com |
| Investor Relations URL | https://investors.abbvie.com |
| HQ State/Province | Illinois |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 06, 2026 (est.) |
| Last Earnings Release | Oct. 31, 2025 |
| Next Ex-Dividend Date | Jan. 16, 2026 |
| Last Ex-Dividend Date | Oct. 15, 2025 |